MAIA Biotechnology, Inc. (MAIA)
ASE · Healthcare · Biotechnology
$1.30
-0.76%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$79.1M
Shares Outstanding
60.8M
Exchange
ASE
Currency
USD
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (9.4M) | (4.0M) | (6.7M) | (8.1M) |
| Net Income | (8.9M) | (3.6M) | (6.4M) | (7.9M) |
| Diluted EPS | $-0.27 | N/A | $-0.14 | $-0.13 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (15.9M) | (20.0M) | (16.9M) | (23.9M) |
| Net Income | (15.8M) | (19.8M) | (23.3M) | (22.4M) |
| Diluted EPS | $-1.75 | $-1.49 | $-1.05 | $-0.70 |